Patents Assigned to Millennium
  • Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
    Patent number: 6420392
    Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: July 16, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Tesfaye Biftu, Xiong Cai, Sajjat Hussoin, Gurmit Grewal, T Y Shen
  • Process control for vinyl acetate manufacture
    Patent number: 6420595
    Abstract: A method of real time process control in a reaction system for the production of vinyl acetate from the oxidation of ethylene and acetic acid. Reaction system samples are collected from the reactor vessel feed and/or effluent and/or from columns and/or transfer lines downstream of the reactor vessel, and the concentration of one or more components in the sample is measured by an infrared analyzer. The concentration measurements are then used to make adjustments in the concentration of components in the reaction system, directly or indirectly, such as by adjusting the temperature profile in a particular column, the flow rate of solution in to or out of a column, or the addition or extraction of a component to or from the solution. For optimum process control, the measurements are transmitted to a control unit for real time analysis, and the adjustments are made almost instantly after the infrared analysis.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: July 16, 2002
    Assignee: Millennium Petrochemicals, Inc.
    Inventors: Noel Hallinan, Wayne Brtko
  • Novel IL-9/IL-2 receptor-like molecules and uses thereof
    Publication number: 20020090680
    Abstract: Novel IL-9/IL-2 receptor-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length IL-9/IL-2 receptor-like proteins, the invention further provides isolated IL-9/IL-2 receptor-like fusion proteins, antigenic peptides, and anti-IL-9/IL-2 receptor-like antibodies. The invention also provides IL-9/IL-2 receptor-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an IL-9/IL-2 receptor-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 26, 2001
    Publication date: July 11, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Novel antibodies and ligands for "Bonzo" chemokine receptor
    Publication number: 20020090657
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR and HBMBU14) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.
    Type: Application
    Filed: August 27, 2001
    Publication date: July 11, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
  • Tango 71 nucleic acids
    Patent number: 6416974
    Abstract: The invention relates to Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83 polypeptides, nucleic acid molecules encoding Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, and uses thereof.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: July 9, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, Andrew D. J. Goodearl
  • 23484, a novel human ubiquitin protease
    Publication number: 20020086407
    Abstract: The present invention relates to a newly identified human ubiquitin protease belonging to the family of mammalian deubiquitinating enzymes. The invention also relates to polynucleotides encoding the ubiquitin protease. The invention further relates to methods using the ubiquitin protease polypeptides and polynucleotides as a target for diagnosis and treatment in ubiquitin-mediated or -related disorders. The invention further relates to drug-screening methods using the ubiquitin protease polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the ubiquitin protease polypeptides and polynucleotides. The invention further relates to procedures for producing the ubiquitin protease polypeptides and polynucleotides.
    Type: Application
    Filed: October 5, 2001
    Publication date: July 4, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Rosana Kapeller-Libermann
  • 25312, a novel human agmatinase-like homolog
    Patent number: 6413757
    Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: July 2, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: William James Cook, Rory A. J. Curtis, Frank Spaltmann
  • Compositions and methods for the treatment and diagnosis of immune disorders
    Patent number: 6414117
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: July 2, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas Adam Levinson
  • 7716, a novel human ATPase and uses therefor
    Publication number: 20020082212
    Abstract: The invention provides isolated nucleic acids molecules, designated 7716 nucleic acid molecules, which encode novel ATPase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7716 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7716 gene has been introduced or disrupted. The invention still further provides isolated 7716 proteins, fusion proteins, antigenic peptides and anti-7716 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 18, 2001
    Publication date: June 27, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Rachel A. Meyers
  • Novel RGS-containing molecules and uses thereof
    Publication number: 20020081683
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 27, 2001
    Publication date: June 27, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, David Yowe
  • NARC8 programmed cell-death-associated molecules and uses thereof
    Publication number: 20020081679
    Abstract: The invention provides isolated nucleic acids molecules, designated NARC8 nucleic acid molecules, which encode novel programmed cell death-associated proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing NARC8 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a NARC8 gene has been introduced or disrupted. The invention still further provides isolated NARC8 proteins, fusion proteins, antigenic peptides and anti-NARC8 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 1, 2001
    Publication date: June 27, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Lillian Wei-Ming Chiang
  • Caspase recruitment domain polypeptides
    Patent number: 6410689
    Abstract: The invention relates to nucleic acid molecules encoding CARD-3, nucleic acid molecules encoding CARD-4, CARD-3 polypeptides, CARD-4 polypeptides, and uses thereof.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: June 25, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • Genes encoding polypeptides containing signal sequences
    Patent number: 6410315
    Abstract: The invention involves a method of identifying nucleic acid sequences encoding signal peptide-containing proteins. The method features chimeric constructs containing a KRE9 gene that lacks a signal sequence. Yeast containing chimeric KRE9 plasmid constructs that encode signal sequences are selected based on their ability to grow on media in which sucrose is the sole carbon source.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: June 25, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Sean A. McCarthy, Steven Bossone
  • Molecules of the follistatin-related protein family and uses thereof
    Patent number: 6410232
    Abstract: Novel FMCP polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length FMCP proteins, the invention further provides isolated FMCP fussion proteins, antigenic peptides and anti-FMCP antibodies. The invention also provides FMCP nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a FMCP gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: June 25, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Douglas A. Holtzman
  • 3700, a novel human protein kinase and uses therefor
    Publication number: 20020077312
    Abstract: The invention provides isolated nucleic acids molecules, designated 3700 nucleic acid molecules, which encode a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 3700 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 3700 gene has been introduced or disrupted. The invention still further provides isolated 3700 proteins, fusion proteins, antigenic peptides and anti-3700 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 25, 2001
    Publication date: June 20, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A.J. Curtis, Katherine M. Galvin
  • 27877, a novel phospholipase and uses therefor
    Publication number: 20020076764
    Abstract: The invention provides isolated nucleic acids molecules, designated 27877 nucleic acid molecules, which encode a novel phospholipase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 27877 gene has been introduced or disrupted. The invention still further provides isolated 27877 proteins, fusion proteins, antigenic peptides and anti-27877 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 10, 2001
    Publication date: June 20, 2002
    Applicant: Millennium pharmaceuticals, Inc.
    Inventors: Rachel A. Meyers, Joseph M. Carroll
  • 2786, a novel human aminopeptidase
    Publication number: 20020076796
    Abstract: The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.
    Type: Application
    Filed: May 14, 2001
    Publication date: June 20, 2002
    Applicant: Millennium Pharmaceuticals
    Inventors: Rosana Kapeller-Libermann, David White, Kyle J. MacBeth
  • Secreted proteins and uses thereof
    Patent number: 6406884
    Abstract: The invention provides isolated nucleic acid molecules, designated TANGO 281, which encode proteins downregulated in megakaryocytes that fail to express the gata-1 transcription factor (a factor critical for blood cell formulation) and can, therefore, represent direct or indirect gata-1 targets. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic polypeptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: June 18, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Steven Bossone
  • Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies
    Patent number: 6406865
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: June 18, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Wine rack
    Patent number: D459640
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: July 2, 2002
    Assignee: Sunhing Millennium Ltd
    Inventors: David Ngai Pun Chung, Ding Hui Li